摘要
背景与目的凡德他尼是抑制血管内皮生长因子受体(vascular endothelial growth factor receptor,VEG-FR)和内皮生长因子受体(endothelial growth factor receptor,EGFR)的小分子药物,本研究旨在系统评价凡德他尼作为二线方案治疗非小细胞肺癌(non-smallcelllungcancer,NSCLC)的有效性和安全性。方法检索PubMed、Medline、Embase、维普、中国期刊全文数据库等数据库,收集凡德他尼治疗NSCLC的随机对照试验,用Revman 5.0软件对数据进行meta分析。结果与对照组(单用一种其它靶向药物或化疗药物)相比,凡德他尼组在疾病无进展生存期(OR=1.23,95%CI:1.05-1.45)、部分缓解(OR=2.15,95%CI:1.59-2.93)、疾病控制(OR=1.22,95%CI:1.06-1.40)、腹泻(OR=1.59,95%CI:1.38-1.83)、恶心(OR=0.69,95%CI:0.57-0.83)、皮疹(OR=2.07,95%CI:1.71-2.49)、便秘(OR=0.81,95%CI:0.67-0.97)、呕吐(OR=0.72,95%CI:0.60-0.87)等方面有统计学差异,但总生存期、疾病稳定、疲乏、咳嗽、食欲减退、呼吸困难等方面无统计学差异。结论凡德他尼作为二线方案治疗晚期NSCLC的疗效有一定的优势,但是其安全性无明显优势。
Background and objective Vandetanib is a small molecule inhibitor against vascular endothelial growth factor receptor（VEGFR）and epidermal growth factor receptor（EGFR）.The aim of this study is to evaluate the efficacy and safety of vandetanib as a second-line treatment for advanced non-small cell lung cancer（NSCLC）. Methods We selected ran-domized controlled trials（RCTs）on vandetanib for NSCLC from PubMed,Medline,Embase,VIP and CNKI.Meta-analysis was completed using software Review Manager 5.0.Results Compared with the control group（single other targeted therapy or chemotherapy group）,there were statistical differences in progression free survival（PFS）（OR=1.23,95%CI：1.05-1.45）,partial response（PR）（OR=2.15,95%CI：1.59-2.93）,disease control（DC）（OR=1.22,95%CI：1.06-1.40）,diarrhea（OR=1.59,95%CI：1.38-1.83）,nausea（OR=0.69,95%CI：0.57-0.83）,rash（OR=2.07,95%CI：1.71-2.49）,constipation（OR=0.81,95%CI：0.67-0.97）,and vomiting（OR=0.72,95%CI：0.60-0.87）in the vandetanib group,but there were no differences in overall survival（OS）,stable disease（SD）,fatigue,cough,anorexia and dyspnea.Conclusion Vandetanib might have more superior efficacy as a second-line treatment for NSCLC,but its advantages in terms of safety were not demonstrated.
出处
《中国肺癌杂志》
CAS
北大核心
2012年第3期172-178,共7页
Chinese Journal of Lung Cancer
